Pipeline & data

Programs in motion.

AmberVax runs a portfolio of internal validation studies and partnered feasibility programs. Selected data is shared with prospective partners under CDA.

Program portfolio

Current programs by stage.

Program

Modality

Stage

Focus

mRNA / LNP — influenza

mRNA

Preclinical

25 °C, 12-month

AAV gene therapy stabilization

Viral vector

Feasibility

Partner program

Recombinant subunit — RSV

Protein subunit

Preclinical

Conformational integrity

High-concentration mAb

Biologic

Partner program

Solid-format prefilled

Live attenuated — measles

Live attenuated

Discovery

WHO ambient target

Cell-derived EVs

Emerging

Discovery

Exploratory

Process

From feasibility to clinical-ready formulation.

Stage 01

Discovery

Stage 02

Feasibility

Stage 03

Preclinical

Stage 04

Partner program

Intellectual property

A consolidated IP estate spanning composition, process and application.

The AmberVax patent estate combines foundational filings from Cyternity and Vitrilife/Vitrisera with newer modality-specific claims. Detailed disclosure available under CDA.